CYCN
NASDAQ
US
Cyclerion Therapeutics, Inc. - Common Stock
$6.15
▼ $-0.23
(-3.61%)
Vol 11.2M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$5.0M
ROE
-24.6%
Margin
-77.0%
D/E
0.00
Beta
0.96
52W
$1–$6
Wall Street Consensus
7 analysts · May 20232
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
AIXC
Aixcrypto Holdings Inc
$12.1M
LIXT
Lixte Biotechnology Holdings Inc
$31.5M
PSTV
Plus Therapeutics Inc
$70.4M
BOLD
Boundless Bio Inc
$26.9M
NEUP
Neuphoria Therapeutics Inc
$20.9M
LGVN
Longeveron Inc
$10.8M
SKYE
Skye Bioscience Inc
$24.0M
VTGN
Vistagen Therapeutics Inc
$26.1M
SNTI
Senti Biosciences Inc
$27.3M
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.39 | $-0.21 | +$0.18 |
| Sep 2025 | — | $-0.30 | — |
| Jun 2025 | — | $-0.11 | — |
| Sep 2023 | $-0.34 | $-0.93 | $-0.59 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $194K | $1.8M | $81K | $93K | $875K |
| Net Income | -$723K | $530K | -$1.4M | -$324K | -$976K |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -22.6% | -22.6% | -22.6% | -22.6% | -24.6% | -24.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -348.4% | -89.5% | -89.5% | -89.5% | -77.0% | -77.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.03 | 5.03 | 5.03 | 5.03 | 5.78 | 5.78 |
Key Ratios
ROA (TTM)
-22.4%
P/S (TTM)
1.75
P/B
1.0
EPS (TTM)
$-0.76
CF/Share
$-7.92
Rev Growth 3Y
-20.2%
52W High
$6.25
52W Low
$1.28
$1.28
52-Week Range
$6.25
Financial Health
Free Cash Flow
-$264K
Cash
$4.6M
As of Sep 30, 2025
How does CYCN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CYCN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.8
▼
86%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.0
▼
60%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CYCN profitability vs Biotechnology peers
ROE
-24.6%
▲
63%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-77.0%
▲
73%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-22.4%
▲
52%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CYCN financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
5.8
▲
30%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
1.0
▼
1%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
CYCN fundamentals radar
CYCN
Peer median
Industry
CYCN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CYCN vs peers: key metrics
Top Holders
Top 5: 6.43%Siren, L.L.C.
2.95%
$174K
Geode Capital Management, L…
1.10%
$65K
Two Sigma Investments, LP
1.06%
$63K
Two Sigma Advisers, LP
0.72%
$43K
Vanguard Group Inc
0.60%
$35K
As of Dec 31, 2025
Latest News
No related news yet